Sorafenib (brand name Nexavar) / HK1 Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱
Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 RAF → MEK → ERK (MAPK) ↓ (primary) ↔ / ↓ (proliferating cells) R/G Reduced proliferative signaling Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2 VEGFR / PDGFR (angiogenesis) ↓ tumor vascularization ↓ endothelial proliferation R/G Anti-angiogenic effect Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3 Intrinsic apoptosis (Mcl-1↓, caspases↑) ↑ ↔ / ↑ (dose-dependent) R/G Mitochondrial apoptosis Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4 ROS ↑ (dose-dependent) ↔ / ↑ (high exposure) P/R Oxidative stress contribution Redox stress may contribute to cytotoxicity and resistance mechanisms.
5 Ferroptosis ↑ (context-dependent) ↔ R/G Lipid peroxidation vulnerability Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6 PI3K/AKT/mTOR ↓ (secondary; model-dependent) ↔ R/G Reduced survival signaling Often compensatory pathway in resistance; combination target in trials.
7 HIF-1α ↓ (anti-angiogenic coupling) ↔ G Reduced hypoxia signaling Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8 NRF2 ↑ (resistance-associated; context-dependent) ↔ R/G Adaptive antioxidant response NRF2 upregulation linked to sorafenib resistance in HCC.
9 Ca²⁺ signaling ↔ (stress-related) ↔ P/R Not primary axis Secondary to mitochondrial stress; not direct target.
10 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Resistance + tolerability limits Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)
HK1, Hexokinase 1: Click to Expand ⟱
Source:
Type:
Accelerated glucose metabolism is a common feature of cancer cells. Hexokinases catalyze the first committed step of glucose metabolism. HK1 (Hexokinase 1) is a key enzyme in glycolysis, catalyzing the phosphorylation of glucose to glucose-6-phosphate. It is critical for maintaining cellular energy homeostasis and is part of the metabolic reprogramming often observed in cancer cells.

• In some tumors, HK1 is upregulated to meet the high glycolytic demands of rapidly proliferating cancer cells. However, the expression pattern can be context-dependent, with some cancers potentially showing moderate or variable HK1 levels compared to the normal tissue counterpart.

• Enhanced HK1 expression supports the high glycolytic flux commonly seen in cancers (the Warburg effect), facilitating anabolic processes and thereby aiding in rapid cell proliferation and biomass accumulation.

• Changes in HK1 expression can also alter the balance between glycolysis and oxidative phosphorylation, potentially impacting reactive oxygen species (ROS) production and cellular redox status in tumors.
Scientific Papers found: Click to Expand⟱
2424- 2DG,  SRF,    The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
- in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
ChemoSen↓, Glycolysis↓, HK1↓, HK2↓, ATP↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HK1↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   HK2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↓, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HK1, Hexokinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:16  Target#:448  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page